EP1011330A4 - Regeneration d'axones dans le systeme nerveux central - Google Patents

Regeneration d'axones dans le systeme nerveux central

Info

Publication number
EP1011330A4
EP1011330A4 EP98943195A EP98943195A EP1011330A4 EP 1011330 A4 EP1011330 A4 EP 1011330A4 EP 98943195 A EP98943195 A EP 98943195A EP 98943195 A EP98943195 A EP 98943195A EP 1011330 A4 EP1011330 A4 EP 1011330A4
Authority
EP
European Patent Office
Prior art keywords
axons
regeneration
veneer system
central veneer
central
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98943195A
Other languages
German (de)
English (en)
Other versions
EP1011330A1 (fr
Inventor
Stephen M Strittmatter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of EP1011330A1 publication Critical patent/EP1011330A1/fr
Publication of EP1011330A4 publication Critical patent/EP1011330A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP98943195A 1997-08-13 1998-08-12 Regeneration d'axones dans le systeme nerveux central Withdrawn EP1011330A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5526897P 1997-08-13 1997-08-13
US55268P 1997-08-13
PCT/US1998/016794 WO1999008533A1 (fr) 1997-08-13 1998-08-12 Regeneration d'axones dans le systeme nerveux central

Publications (2)

Publication Number Publication Date
EP1011330A1 EP1011330A1 (fr) 2000-06-28
EP1011330A4 true EP1011330A4 (fr) 2001-05-16

Family

ID=21996779

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98943195A Withdrawn EP1011330A4 (fr) 1997-08-13 1998-08-12 Regeneration d'axones dans le systeme nerveux central

Country Status (5)

Country Link
EP (1) EP1011330A4 (fr)
JP (1) JP2001515018A (fr)
AU (1) AU735607B2 (fr)
CA (1) CA2300878A1 (fr)
WO (1) WO1999008533A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2214841A1 (fr) * 1997-10-31 1999-04-30 Lisa Mckerracher Les antagonistes rho et leurs utilisations pour arreter l'inhibition d'excroissance d'axone et des dendrites
US7169783B2 (en) 1998-11-02 2007-01-30 Universite De Montreal (+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion
CA2325842C (fr) 2000-11-02 2007-08-07 Lisa Mckerracher Methodes de production et d'administration de preparations combinant un antagoniste de rho et un adhesif tissulaire aux systemes nerveux central et peripherique blesses de mammiferes et utilisations de ces preparations
DE10064195A1 (de) * 2000-12-22 2002-07-11 Migragen Ag Verwendung einer Zusammensetzung zur Stimulation des Nervenwachstums, zur Inhibition der Narbengewebsbildung und/oder Reduktion eines Sekundärschadens
US7795218B2 (en) 2001-04-12 2010-09-14 Bioaxone Therapeutique Inc. ADP-ribosyl transferase fusion variant proteins
CA2367636C (fr) 2001-04-12 2010-05-04 Lisa Mckerracher Proteines de fusion
US7442686B2 (en) 2001-04-12 2008-10-28 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
WO2003030836A2 (fr) 2001-10-12 2003-04-17 Case Western Reserve University Regeneration neuronale
EP1334729A1 (fr) * 2002-02-07 2003-08-13 Botulinum Toxin Research Associates, Inc. Utilisation thérapeutique de non-neurotoxic botulinum clostridium toxine type C2
CN1681525A (zh) * 2002-07-12 2005-10-12 曹义海 一种抑制血管渗漏和组织水肿的方法
GB0216865D0 (en) * 2002-07-19 2002-08-28 Microbiological Res Authority Targetted agents for nerve regeneration
EP2002005A4 (fr) * 2006-03-17 2009-12-09 Univ Mcgill Identification de la protéine crmp4 en tant que régulateur convergent de l'inhibition de la croissance des axones
US20160051644A1 (en) * 2013-01-16 2016-02-25 Bal Ram Singh Botulinum Chimera Compositions for Axonal Regenerative Therapy During Spinal Cord Injury
US10287346B2 (en) 2015-04-28 2019-05-14 Mitsubishi Tanabe Pharma Corporation RGMa binding protein and use thereof
EP3355898B1 (fr) 2015-10-02 2020-11-25 The Regents of the University of California Cellules progénitrices enrichies en cellules gliales dérivées de cellules souches pluripotentes induites pour le traitement d'un avc affectant la substance blanche

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672344A (en) * 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5661033A (en) * 1992-11-25 1997-08-26 The Board Of Trustees Of The Leland Stanford Junior University Gene transfer using herpes virus vectors as a tool for neuroprotection
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
AU1304895A (en) * 1993-12-07 1995-06-27 General Hospital Corporation, The Peptides to overcome inhibition of nerve growth

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
K. JALINK, E.J. VAN CORVEN ET AL.: "Inhibition of lysophosphatidate-and thrombin-induced neurite retraction and neuronal cell rounding by ADP ribosylation of the small GTP-binding protein rho", JOURNAL OF CELL BIOLOGY, vol. 126, no. 3, August 1994 (1994-08-01), pages 801 - 810, XP002915256 *
MARTIN F.B.G. GEBBINK, ET AL.: "Identification of a novel, putative rho-specific GDP/GTP exchange factor and a rhoA-binding protein: control of neuronal morphology", JOURNAL OF CELL BIOLOGY, vol. 137, no. 7, 30 July 1997 (1997-07-30), pages 1603 - 1613, XP000984783 *
P. LAMOUREUX, ET AL.: "Rac is required for growth cone function but not neurite assembly", JOURNAL OF CELL SCIENCE, vol. 110, March 1997 (1997-03-01), pages 635 - 641, XP000984782 *
R. KOZMA, ET AL.: "Rho family GTPases and neuronal growth cone remodelling: Relationship between increased complexity induced by cdc42Hs, Rac1, and acetylcholine and collapse induced by rhoA and lysophosphatidic acid", MOLECULAR AND CELLULAR BIOLOGY, vol. 17, no. 3, March 1997 (1997-03-01), pages 1201 - 1211, XP000984781 *
See also references of WO9908533A1 *

Also Published As

Publication number Publication date
WO1999008533A1 (fr) 1999-02-25
AU9104298A (en) 1999-03-08
AU735607B2 (en) 2001-07-12
EP1011330A1 (fr) 2000-06-28
JP2001515018A (ja) 2001-09-18
CA2300878A1 (fr) 1999-02-25

Similar Documents

Publication Publication Date Title
DE69725205D1 (de) Befestigung von Biomolekülen
DE69718393D1 (de) Befestigung von Biomolekülen
DE19581860T1 (de) Lösen von verklebten Scheiben
FI954880L (fi) Käsiteltyjä epäorgaanisia kiintoaineita
DE19882125T1 (de) Direkte Abscheidung von Palladium
FI964713A0 (fi) Ripustusteline
NO983266D0 (no) Distribuert Behandling
NO975263D0 (no) Aktiviseringskule
DE69612480D1 (de) Detektion von sprechaktivität
DE69820635D1 (de) Geträgerte diole
BR9707687A (pt) Fotocatalisador aniônico
EP1011330A4 (fr) Regeneration d'axones dans le systeme nerveux central
DE69724981D1 (de) Epoxysynthese mit regenerierung der titansilikalitkatalysatoren
DE69830710D1 (de) Bremskraftkontroller
DE69834775D1 (de) Furnierschälmaschine
NO983263D0 (no) Distribuert behandling
DE69815165D1 (de) Aufhängungssystem
DE69719749D1 (de) Aufhängevorrichtung
DE69835081D1 (de) Bremskraftregler
DE69826878D1 (de) Wiederkodierung von dekodierten signalen
DE59706515D1 (de) Einzelradaufhängung
DE69823718D1 (de) Bestrahlungsvorrichtung
FI965285L (fi) Kannatinpalkki
DE69709159D1 (de) Kreuz-dimierisierung von olefinen
DE69602155D1 (de) Verbesserung von Branntweinen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000310

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010403

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20021216

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040518